By CHAD BRAYAPRIL 27, 2015
LONDON — The biopharmaceutical maker Swedish Orphan Biovitrum said on Monday that it had received a preliminary takeover offer from an unnamed suitor.Shares of the company, also known as Sobi, jumped 19.2 percent to 133.10 Swedish kronor in morning trading in Stockholm. That would give it a market capitalization of 35.9 billion kronor, or about $4.2 billion.Sobi, based in Stockholm, did not name the potential acquirer or the price it was willing to pay in a preliminary, nonbinding takeover bid.“There can be no certainty that an offer will be made, nor as to the terms of any such offer,” Sobi said in a news release on Monday.AdvertisementIf a deal is consummated, it would be the latest transaction in what has been a red-hot market for mergers and acquisitions in the health care sector this year, including deals worth $193.9 billion, double the pace at this point in 2014, according to the latest data from Thomson Reuters.Founded in 2001, Sobi focuses on developing treatments for rare diseases and manufactures ReFacto AF, a treatment for the blood-clotting disorder hemophilia, for the drug giant Pfizer.AdvertisementThe company had revenue of 2.6 billion kronor in 2014 and employs about 589 people.A version of this article appears in print on April 28, 2015, on Page B5 of the New York edition with the headline: Sobi Gets Offer.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.